MCID: PPL022
MIFTS: 55

Papilloma malady

Categories: Cancer diseases

Aliases & Classifications for Papilloma

Aliases & Descriptions for Papilloma:

Name: Papilloma 12 52 14 69
Papillomatosis 12 52 14 69
Papillomatosis, Nos 12
Papillomatosis Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2615
MeSH 42 D010212
NCIt 47 C3713 C7440

Summaries for Papilloma

Disease Ontology : 12 A cell type benign neoplam that is composed_of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary : Papilloma, also known as papillomatosis, is related to skin papilloma and maxillary sinus schneiderian papilloma. An important gene associated with Papilloma is UBE3A (Ubiquitin Protein Ligase E3A), and among its related pathways/superpathways are Developmental Biology and Pathways in cancer. The drugs Cervarix and Cidofovir have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and cervix, and related phenotypes are Increased shRNA abundance (Z-score > 2) and growth/size/body region

Wikipedia : 71 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Related Diseases for Papilloma

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 381)
id Related Disease Score Top Affiliating Genes
1 skin papilloma 33.2 KRT13 KRT14 KRT20 KRT5
2 maxillary sinus schneiderian papilloma 33.1 KRT13 KRT5
3 nasopharyngeal carcinoma 29.6 CDKN1A CDKN2A PTEN TP53
4 basaloid squamous cell carcinoma 29.5 KRT10 KRT14 KRT5
5 choroid plexus papilloma 12.4
6 inverted papilloma 12.2
7 squamous cell papilloma 12.2
8 intraductal papilloma 12.1
9 bladder transitional cell papilloma 11.9
10 transitional papilloma 11.9
11 atypical choroid plexus papilloma 11.9
12 breast duct papilloma 11.8
13 frontal sinus inverted papilloma 11.8
14 maxillary sinus inverted papilloma 11.8
15 sphenoid sinus inverted papilloma 11.8
16 serous surface papilloma 11.8
17 ureter inverted papilloma 11.7
18 nasal vestibule papilloma 11.7
19 inverted transitional papilloma 11.7
20 central breast papilloma 11.7
21 urethra inverted papilloma 11.7
22 vaginal mullerian papilloma 11.7
23 ureter urothelial papilloma 11.7
24 frontal sinus schneiderian papilloma 11.7
25 vaginal squamous papilloma 11.7
26 renal pelvis inverted papilloma 11.7
27 squamous cell papilloma of skin 11.7
28 sphenoid sinus schneiderian papilloma 11.7
29 ethmoid sinus schneiderian papilloma 11.7
30 ethmoid sinus inverted papilloma 11.7
31 cervical mullerian papilloma 11.7
32 cervix squamous papilloma 11.7
33 urethral urothelial papilloma 11.6
34 fallopian tube serous papilloma 11.6
35 esophagus squamous cell papilloma 11.6
36 verrucous papilloma 11.6
37 renal pelvis urothelial papilloma 11.6
38 ovarian surface papilloma 11.6
39 sclerosing breast papilloma 11.6
40 nasal cavity inverting papilloma 11.6
41 urinary bladder inverted papilloma 11.6
42 microscopic breast papilloma 11.6
43 bladder squamous papilloma 11.6
44 vulvar squamous papilloma 11.6
45 atypical breast papilloma 11.6
46 larynx squamous papilloma 11.6
47 recurrent respiratory papillomatosis 11.6
48 laryngeal papillomatosis 11.4
49 focal dermal hypoplasia 11.1
50 focal epithelial hyperplasia 11.1

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma

Symptoms & Phenotypes for Papilloma

GenomeRNAi Phenotypes related to Papilloma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.87 CD209
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.87 CD209 RB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.87 CDKN1A
4 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.87 KRT13
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.87 RB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.87 CD209
7 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.87 RB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.87 UBE3A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.87 RB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.87 RB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.87 CD209
12 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.87 KRT13
13 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.87 UBE3A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.87 KRT13
15 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.87 RB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.87 CD209
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.87 CDKN1A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.87 KRT13
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.87 CD209
20 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.87 CDKN1A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.87 UBE3A
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 CD209 RB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.87 RB1 UBE3A CD209 CDKN1A KRT13
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.87 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.87 UBE3A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.87 CDKN1A
27 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.87 CD209 KRT13
28 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.87 CDKN1A

MGI Mouse Phenotypes related to Papilloma:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 PTEN RB1 TP53 UBE2L3 UBE3A AMOT
2 digestive/alimentary MP:0005381 10.21 CDKN1A CDKN2A IGF2 IL4 KRT14 KRT5
3 mortality/aging MP:0010768 10.18 AMOT CDKN1A CDKN2A IGF2 IL4 KRT14
4 embryo MP:0005380 10.15 AMOT CDKN1A CDKN2A IGF2 KRT8 PTEN
5 endocrine/exocrine gland MP:0005379 10.13 TP53 UBE3A CDKN1A CDKN2A IGF2 IL4
6 integument MP:0010771 10.13 CDKN1A CDKN2A IGF2 IL4 KRT14 KRT5
7 craniofacial MP:0005382 10.07 CDKN1A IGF2 IL4 KRT14 KRT5 RB1
8 liver/biliary system MP:0005370 10.01 CDKN1A CDKN2A IGF2 IL4 KRT8 PTEN
9 no phenotypic analysis MP:0003012 9.92 CDKN1A CDKN2A IGF2 IL4 KRT5 RB1
10 reproductive system MP:0005389 9.85 CDKN1A CDKN2A IGF2 IL4 KRT14 KRT8
11 pigmentation MP:0001186 9.65 CDKN2A KRT14 PTEN RB1 TP53
12 respiratory system MP:0005388 9.56 TP53 CDKN1A CDKN2A IGF2 IL4 KRT14
13 vision/eye MP:0005391 9.23 TP53 CDKN1A CDKN2A IGF2 IL4 KRT14

Drugs & Therapeutics for Papilloma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Cervarix 17 46 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline Approved October 2009

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cidofovir Approved Phase 4,Phase 2,Phase 1 113852-37-2 60613
2
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
3
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3 99011-02-6 57469
4 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
6 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
7 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
9 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
10 Anti-Infective Agents, Local Phase 4
11 Chlorhexidine gluconate Phase 4
12 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Disinfectants Phase 4
14 Polyhexamethylene biguanide Phase 4
15 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
16 MF59 oil emulsion Phase 4
17 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1
18 Interferon Inducers Phase 4,Phase 2,Phase 3,Phase 1
19 interferons Phase 4,Phase 2,Phase 3,Phase 1
20
Aminolevulinic acid Approved Phase 3 106-60-5 137
21
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
23
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
24
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
25
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
26
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
27
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
28
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
29
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
30
Azithromycin Approved Phase 3 83905-01-5 55185 53477736 447043
31
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
32
Doxepin Approved Phase 3 1668-19-5 667477 667468
33
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
34
Zinc Approved Phase 3 7440-66-6 32051 23994
35 Zinc sulfate Approved Phase 3 7733-02-0
36 tannic acid Approved, Nutraceutical Phase 3
37
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
38 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
39 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
40 Adjuvants, Anesthesia Phase 3
41 Analgesics Phase 3,Phase 2,Phase 1
42 Analgesics, Opioid Phase 3
43 Anesthetics Phase 3
44 Anesthetics, General Phase 3
45 Anesthetics, Intravenous Phase 3
46 Central Nervous System Depressants Phase 3
47 Narcotics Phase 3
48 pancreatic polypeptide Phase 3
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 Autonomic Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 349)
id Name Status NCT ID Phase
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men Completed NCT01431079 Phase 4
4 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
5 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
6 Use of Cidofovir for Recurrent Respiratory Papillomatosis Completed NCT00205374 Phase 4
7 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
8 MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Completed NCT02225327 Phase 4
9 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
10 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Recruiting NCT02087384 Phase 4
11 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4
12 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
13 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4
14 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
15 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
16 Topical 5-ALA Photodynamic Therapy for the Treatment of Verruca Vulgaris Unknown status NCT00155584 Phase 3
17 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3
18 Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine Completed NCT00316706 Phase 3
19 Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. Completed NCT00196924 Phase 3
20 Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 Completed NCT00169494 Phase 3
21 Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) Completed NCT00380367 Phase 3
22 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
23 Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 Completed NCT00196937 Phase 3
24 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3
25 A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men Completed NCT02114385 Phase 3
26 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
27 Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years Completed NCT00345878 Phase 3
28 Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women Completed NCT00344032 Phase 3
29 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
30 Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) Completed NCT00157950 Phase 3
31 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects Completed NCT00578227 Phase 3
32 A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years Completed NCT00485732 Phase 3
33 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
34 An Investigational Study of Gardasil™ (qHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
35 Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age Completed NCT00552279 Phase 3
36 Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls Completed NCT01381575 Phase 3
37 ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial Completed NCT00941252 Phase 2, Phase 3
38 A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). Completed NCT01254643 Phase 3
39 Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age Completed NCT00492544 Phase 3
40 A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3
41 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3
42 Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Completed NCT01164722 Phase 3
43 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
44 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
45 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
46 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
47 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
48 Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Completed NCT00456807 Phase 3
49 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects Completed NCT00426361 Phase 3
50 Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Papilloma

Anatomical Context for Papilloma

MalaCards organs/tissues related to Papilloma:

39
Breast, Skin, Cervix, Bone, Lung, Testes, Prostate

Publications for Papilloma

Articles related to Papilloma:

(show top 50) (show all 1766)
id Title Authors Year
1
Will they lead by example? Assessment of vaccination rates and attitudes to human papilloma virus in millennial medical students. ( 28056900 )
2017
2
Ultrasonic elastography exploration of the foetal brain: A case of atypical choroid plexus papilloma. ( 28421905 )
2017
3
Intention of Mothers in Israel to Vaccinate their Sons against the Human Papilloma Virus. ( 28081933 )
2017
4
Ossifying inverted papilloma and ossifying polypA of the sinonasal tract: comparison ofA CTA andA MRI features. ( 27773333 )
2017
5
Choroid plexus papilloma. ( 28413558 )
2017
6
Esophageal Squamous Cell Papilloma. ( 27751518 )
2017
7
Knowledge, Behaviors, and Attitudes About Human Papilloma Virus Among Nursing Students in Izmir, Turkey. ( 28074443 )
2017
8
Knowledge of Greek adolescents on human papilloma virus (HPV) and vaccination: A national epidemiologic study. ( 28072683 )
2017
9
Esophageal squamous papillomas with focal dermal hypoplasia and eosinophilic esophagitis. ( 28405153 )
2017
10
Genetic Mutation and Exosome Signature of Human Papilloma Virus Associated Oropharyngeal Cancer. ( 28383029 )
2017
11
TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. ( 28040359 )
2017
12
Gene promoter methylation and protein expression of BRMS1 in uterine cervix in relation to high-risk human papilloma virus infection and cancer. ( 28381193 )
2017
13
Atypical choroid plexus papilloma: clinicopathological and neuroradiological features. ( 28358248 )
2017
14
Human Papilloma Virus Vaccination and Incidence of Ocular Surface Squamous Neoplasia. ( 27898614 )
2017
15
Lesson of the month 2: A choroid plexus papilloma manifesting as anorexia nervosa in an adult. ( 28365635 )
2017
16
Human papilloma virus infection and cervical cytomorphological changing among intrauterine contraception users. ( 27649651 )
2016
17
Spinal seeding of choroid plexus papilloma. ( 26804647 )
2016
18
Sinonasal inverted papilloma: From diagnosis to treatment. ( 27053431 )
2016
19
Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. ( 27098388 )
2016
20
Re-affirming the necessity of sending even minor surgical specimens for histopathology: a case of inverted papilloma of the adenoids. ( 27685930 )
2016
21
Assessment of the incidence of squamous cell papilloma of the esophagus and the presence of high-risk human papilloma virus. ( 27001250 )
2016
22
Inverted Papilloma of the Bladder Coexisting with Urothelial Carcinoma. A Case Report. ( 27363067 )
2016
23
Typical Symptoms of Normal-Pressure Hydrocephalus Caused by Choroid Plexus Papilloma in the Cerebellopontine Angle. ( 27913261 )
2016
24
A functional polymorphism in the NKG2D gene modulates NK-cell cytotoxicity and is associated with susceptibility to Human Papilloma Virus-related cancers. ( 27995954 )
2016
25
Floor of Mouth Mass. Intraductal papilloma. ( 26583524 )
2016
26
Black raspberries demethylate Sfrp4, a WNT pathway antagonist, in rat esophageal squamous cell papilloma. ( 27696538 )
2016
27
Smoking, not human papilloma virus infection, is a risk factor for recurrence of sinonasal inverted papilloma. ( 26980388 )
2016
28
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status. ( 27083677 )
2016
29
Primary Inverted Papilloma of Middle Ear and Mastoid: A Rare Case Report. ( 27190934 )
2016
30
CD40/CD40 ligand interactions and TNFI+ treatment reduce activity of P105 promoter of the human papilloma virus-18 in vitro. ( 27031714 )
2016
31
Intestinal Type Adenocarcinoma from Inverted Papilloma: A Rare Recurrence. ( 28050382 )
2016
32
Survival outcomes after endoscopic resection for sinonasal squamous cell carcinoma arising on inverted papilloma. ( 27152722 )
2016
33
Rare subtype(s) and frequency of multi-viral subtype high-risk human papilloma virus infection in high-grade squamous intraepithelial lesion and squamous cell carcinoma in a cervical carcinoma prevalent developing country: a multiplex real-time polymerase chain reaction-based pilot study. ( 27659129 )
2016
34
Uncommon presentation of choroid plexus papilloma in an infant. ( 27195037 )
2016
35
Squamous cell carcinoma antigen as a diagnostic marker of nasal inverted papilloma. ( 26877539 )
2016
36
High-definition dacryoendoscopic features of a canalicular squamous papilloma. ( 27990621 )
2016
37
Partial glossectomy for treating extensive oral squamous cell papilloma. ( 27544018 )
2016
38
Metachronous Type I pleuropulmonary blastoma and atypical choroid plexus papilloma in a young child. ( 27442759 )
2016
39
Retrospective analysis of oncogenic human papilloma virus and Epstein-Barr virus prevalence in Turkish nasopharyngeal cancer patients. ( 27640103 )
2016
40
Management Strategies for Skull Base Inverted Papilloma. ( 27026729 )
2016
41
Primary inverted papilloma of the middle ear with intracranial invasion. ( 26698908 )
2016
42
Recurrence of sinonasal inverted papilloma following surgical approach: A meta-analysis. ( 27531693 )
2016
43
Human Papilloma Virus Detection by INNOLiPA HPV in Prostate Tissue from Men of Northeast Mexico ( 28030912 )
2016
44
Periodontal pocket as a potential reservoir of high risk human papilloma virus: A pilot study. ( 27143823 )
2016
45
Attenuation of DMBA/croton oil induced mouse skin papilloma by Apodytes dimidiata mediated by its antioxidant and antimutagenic potential. ( 26878464 )
2016
46
Migration of a lateral ventricular choroid plexus papilloma: An uncommon occurrence. ( 27381143 )
2016
47
Co-occurrence of bronchial papilloma and pulmonary sclerosing hemangioma in a male. ( 27812454 )
2016
48
Diversity of high risk human papilloma viruses in women treated with antiretroviral and in healthy controls and discordance with cervical dysplasia in the South of Benin. ( 27528886 )
2016
49
On vaccination programs in the EU Member States: the case of the human papilloma virus. ( 27928744 )
2016
50
Squamous papilloma of esophagus. ( 27138928 )
2016

Variations for Papilloma

Expression for Papilloma

Search GEO for disease gene expression data for Papilloma.

Pathways for Papilloma

Pathways related to Papilloma according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 FLG IVL KRT10 KRT13 KRT14 KRT20
2 12.6 CDKN1A CDKN2A PTEN RB1 TP53
3 12.36 CDKN1A CDKN2A RB1 TP53
4 12.36 AMOT KRT10 KRT13 KRT20 KRT5 KRT8
5
Show member pathways
12.33 CDKN1A IGF2 IL4 PTEN TP53
6 12.3 CDKN1A CDKN2A RB1 TP53
7
Show member pathways
12.3 CDKN1A CDKN2A PTEN RB1 TP53
8
Show member pathways
12.28 CDKN1A CDKN2A RB1 TP53
9
Show member pathways
12.19 CDKN1A PTEN RB1 TP53
10 12.18 CDKN1A CDKN2A RB1 TP53 UBE3A
11
Show member pathways
12.11 CDKN1A PTEN RB1 TP53
12
Show member pathways
12.04 CDKN1A CDKN2A RB1 TP53
13 12.02 CDKN1A CDKN2A PTEN TP53
14 12 CDKN1A PTEN RB1 TP53
15 11.93 CDKN1A CDKN2A PTEN TP53
16
Show member pathways
11.89 KRT13 KRT14 KRT5 KRT8
17 11.78 CDKN1A PTEN RB1 UBE3A
18 11.77 CDKN1A RB1 TP53
19 11.75 PTEN RB1 TP53
20 11.68 CDKN1A CDKN2A PTEN RB1 TP53
21
Show member pathways
11.68 FLG IVL KRT10 KRT13 KRT14 KRT20
22 11.66 CDKN1A CDKN2A TP53
23 11.62 CDKN1A CDKN2A RB1 TP53
24 11.56 CDKN1A CDKN2A RB1 TP53 UBE3A
25 11.48 CDKN1A CDKN2A IGF2 PTEN RB1 TP53
26 11.47 CDKN1A IL4 KRT14 KRT5 TP53
27 11.38 CDKN1A CDKN2A RB1 TP53
28 11.29 CDKN1A PTEN RB1 TP53
29 11.03 CDKN2A RB1 TP53
30
Show member pathways
11.01 CDKN1A CDKN2A TP53
31 10.72 CDKN1A TP53
32
Show member pathways
10.52 CDKN1A TP53

GO Terms for Papilloma

Cellular components related to Papilloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.83 AMOT CDKN1A CDKN2A FLG IVL KRT10
2 keratin filament GO:0045095 9.46 KRT13 KRT14 KRT5 KRT8
3 cornified envelope GO:0001533 9.43 FLG IVL KRT10
4 intermediate filament GO:0005882 9.17 FLG KRT10 KRT13 KRT14 KRT20 KRT5

Biological processes related to Papilloma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.89 CD209 KRT8 RB1 TP53 UBE3A
2 negative regulation of cell proliferation GO:0008285 9.88 CDKN1A CDKN2A PTEN RB1 TP53
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.74 IGF2 IL4 TP53
4 keratinocyte differentiation GO:0030216 9.7 FLG IVL KRT10
5 cell cycle arrest GO:0007050 9.67 CDKN1A CDKN2A RB1 TP53
6 peptide cross-linking GO:0018149 9.61 FLG IVL KRT10
7 response to arsenic-containing substance GO:0046685 9.56 CDKN1A PTEN
8 Ras protein signal transduction GO:0007265 9.56 CDKN1A CDKN2A RB1 TP53
9 hepatocyte apoptotic process GO:0097284 9.55 KRT8 RB1
10 hemidesmosome assembly GO:0031581 9.54 KRT14 KRT5
11 skin epidermis development GO:0098773 9.51 FLG KRT10
12 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.5 CDKN1A PTEN RB1
13 keratinization GO:0031424 9.5 IVL KRT10 KRT13 KRT14 KRT20 KRT5
14 prostate gland growth GO:0060736 9.46 PTEN UBE3A
15 signal transduction by p53 class mediator GO:0072331 9.4 CDKN1A TP53
16 replicative senescence GO:0090399 9.33 CDKN1A CDKN2A TP53
17 cornification GO:0070268 9.23 FLG IVL KRT10 KRT13 KRT14 KRT20

Molecular functions related to Papilloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 AMOT CD209 CDKN1A CDKN2A FLG IGF2
2 structural constituent of epidermis GO:0030280 9.26 FLG KRT10
3 structural molecule activity GO:0005198 9.26 FLG IVL KRT13 KRT8
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.16 CDKN1A CDKN2A

Sources for Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....